Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma

N Engl J Med. 2018 Apr 19;378(16):1560-1561. doi: 10.1056/NEJMc1802363.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Brentuximab Vedotin
  • Hodgkin Disease*
  • Humans
  • Immunoconjugates*

Substances

  • Antineoplastic Agents
  • Immunoconjugates
  • Brentuximab Vedotin